NYSE · ISRG
Healthcare · Medical - Instruments & Supplies
$448.76
Down-$16.75 (-3.73%)
Updated Oct 31, 2026, 12:07 AM
SID Score
5.2/10
Composite research score
Smart Money
39/100
Bearish
Price performance · ISRG
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
ISRG closed at $448.76 after 20 trading sessions, up 14.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $447.85 | $450.40 | $443.475 | $448.76 | 1.89M |
| Oct 28, 2026 | $441.425 | $449.97 | $437.5101 | $444.18 | 1.85M |
| Oct 27, 2026 | $451.63 | $451.63 | $443.8501 | $445.88 | 1.7M |
| Oct 26, 2026 | $451.93 | $458.88 | $447.61 | $451.63 | 3.07M |
| Oct 23, 2026 | $443.65 | $458.45 | $442.56 | $452.29 | 3.01M |
| Oct 22, 2026 | $430.745 | $444.15 | $427.47 | $443.85 | 2.78M |
| Oct 21, 2026 | $402.495 | $432.7492 | $398.992 | $428.12 | 4.8M |
| Oct 20, 2026 | $433.502 | $440.40 | $432.00 | $438.00 | 3.44M |
| Oct 19, 2026 | $428.79 | $434.622 | $426.70 | $433.18 | 2.53M |
| Oct 16, 2026 | $428.43 | $434.89 | $425.51 | $426.70 | 2.61M |
| Oct 15, 2026 | $425.50 | $429.89 | $419.54 | $427.86 | 2.06M |
| Oct 14, 2026 | $424.81 | $425.50 | $414.65 | $420.24 | 1.92M |
| Oct 13, 2026 | $430.00 | $430.00 | $416.37 | $422.06 | 1.74M |
| Oct 12, 2026 | $423.00 | $429.27 | $421.03 | $427.64 | 1.62M |
| Oct 9, 2026 | $416.39 | $427.53 | $415.855 | $423.96 | 1.76M |
| Oct 8, 2026 | $411.60 | $416.72 | $407.70 | $415.41 | 2.53M |
| Oct 7, 2026 | $405.07 | $416.81 | $404.20 | $414.52 | 1.9M |
| Oct 6, 2026 | $405.20 | $409.34 | $402.00 | $404.76 | 1.65M |
| Oct 5, 2026 | $389.76 | $407.63 | $389.11 | $406.48 | 1.66M |
| Oct 2, 2026 | $405.15 | $406.47 | $391.39 | $391.95 | 1.83M |
The latest Smart Investors Daily articles mentioning ISRG.
Company
Market Activity
Research & News
ISRG research
Company profile and research snapshot.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | Evercore ISI Group | In-Line | — |
| Oct 21, 2026 | Barclays | Overweight | — |
| Oct 21, 2026 | TD Cowen | Buy | — |
| Oct 21, 2026 | Wells Fargo | Overweight | — |
| Oct 21, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 30, 2026
Intuitive Surgical's surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific despite its valuation premium.
Yahoo · Oct 30, 2026
DVA's Q3 earnings surge 52.2% as revenues rise 4.6%, fueled by strong kidney care and international growth despite rising costs and margin pressure.
Yahoo · Oct 29, 2026
Intuitive Surgical's third-quarter sales surged 22%, outpacing procedure growth. Can system placements, new technologies and recurring revenues offset pricing pressures?
Yahoo · Oct 29, 2026
BAX beats Q3 earnings and revenue estimates, driven by broad-based segment growth, and raises its 2026 outlook despite continued margin pressure.
Interpretive context generated from the platform’s current data sources.
Intuitive Surgical shares closed at $448.76, declining 0.85% in the most recent session, per SID market data. Despite the daily pullback, the stock has demonstrated strong momentum over intermediate timeframes, gaining 7.76% over the past month and 25.84% over the trailing three months. However, on a one-year basis, ISRG remains down 21.58%, reflecting broader volatility in high-multiple healthcare names. Technically, the stock trades well above its 50-day moving average of $399.37 and above its 200-day moving average of $432.17, suggesting a constructive trend structure, according to Massive/Polygon data. The 14-day RSI reads 67.6, approaching but not yet in overbought territory. ISRG carries a beta of 1.686, indicating substantially higher volatility than the broader market. Average daily trading volume stands at approximately 2.26 million shares, supporting adequate liquidity for institutional positioning.
Intuitive Surgical commands a market capitalization of approximately $195.5 billion, positioning it among the largest pure-play medical device companies globally, per SID market data. The stock trades at a trailing price-to-earnings ratio of 71.05, reflecting a significant premium relative to the broader Healthcare sector. The PEG ratio stands at 13.30, according to SEC filings and consensus growth estimates, indicating that even when adjusted for expected earnings growth, the valuation remains elevated. Additionally, ISRG trades at a price-to-book ratio of 11.53, underscoring the market's substantial premium placed on the company's intangible assets, including its dominant da Vinci surgical platform and installed base economics. The company pays no dividend, consistent with its strategy of reinvesting capital into research, development, and platform expansion. These metrics collectively reflect a growth-oriented valuation profile that prices in continued procedural volume expansion and system placements.
Intuitive Surgical's composite smart money score stands at 39 out of 100, generating a bearish signal, per SID market data. The score reflects divergent trends across investor categories. Institutional positioning scores a perfect 25 out of 25, indicating robust demand from large fund managers who continue to accumulate shares. However, insider activity scores just 5.0 out of 25, with SEC Form 4 filings revealing 20 insider transactions over the past 90 days — comprising 7 purchases against 13 sales. This nearly two-to-one sell-to-buy ratio suggests company executives and directors have been net reducers of their holdings. Dark pool activity registers at 8.5 out of 25, indicating below-average institutional block-trade accumulation in off-exchange venues, according to 13F institutional filings. Congressional trading activity scores a minimal 0.8 out of 25, showing negligible legislative interest. The divergence between strong institutional ownership and elevated insider selling creates a mixed directional signal for ISRG.
Intuitive Surgical has delivered a consistent pattern of earnings outperformance across recent quarters, according to company earnings reports. In the most recent reported quarter, the company posted earnings per share of $3.00 against a consensus estimate of $2.54, representing a positive surprise of $0.46, or approximately 18.1%. The prior quarter saw EPS of $2.80 versus expectations of $2.41, a beat of $0.39. Two quarters ago, the company reported $2.50 per share against an estimate of $1.92, delivering the largest surprise at $0.58, or roughly 30.2%. This three-quarter streak of double-digit percentage beats demonstrates operational execution and suggests analyst models may be systematically underestimating procedure volume growth and margin expansion. Looking ahead, analysts estimate EPS of $2.41 for the upcoming quarter with results expected on July 21, per analyst estimates. The trajectory of upward surprises will be closely monitored for continuation.
Wall Street consensus on Intuitive Surgical remains predominantly constructive, per Wall Street analyst reports. Following the most recent earnings release, five major firms issued updated ratings on October 21, 2026. Barclays and Wells Fargo both reiterated Overweight ratings, while RBC Capital maintained its Outperform designation and TD Cowen reaffirmed a Buy recommendation, according to SID consensus data. Evercore ISI Group was the lone neutral voice, maintaining its In-Line rating. Notably, none of the five analysts changed their prior ratings, suggesting the earnings beat largely aligned with bullish theses already embedded in existing coverage. The four-to-one ratio of positive-to-neutral ratings reflects broad confidence in Intuitive Surgical's competitive moat in robotic-assisted surgery. No analyst carried a negative or underweight rating among the recent updates. The clustering of reaffirmations rather than upgrades may indicate that at a P/E of 71.05, the stock's premium valuation is already well understood by the Street.
The latest Smart Investors Daily articles mentioning ISRG.
